Vera Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Vera Therapeutics, Inc. (VERA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 12.11 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 12.11M shares, a 27.61% increase year-over-year.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.84M shares, a 34.91% increase year-over-year.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 9.94M shares, a 42.53% increase year-over-year.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 9.49M shares, a 40.78% increase year-over-year.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.02M shares, a 36.99% increase from fiscal 2024.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 7.32M shares, a 24.15% increase from fiscal 2023.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.89M shares, a 46.41% increase from fiscal 2022.
- Vera Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.03M shares, a 37.66% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 12.11M shares 10-Q · filed 2026-08-10 | 12.11M shares 10-Q · filed 2026-08-10 | |||||
| 2026-03-31 | 11.84M shares 10-Q · filed 2026-05-07 | ||||||
| 2025-12-31 | 10.02M shares 10-K · filed 2026-02-26 | ||||||
| 2025-09-30 | 9.94M shares 10-Q · filed 2025-11-05 | 9.94M shares 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | 9.49M shares 10-Q · filed 2026-08-10 | 9.49M shares 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | 8.77M shares 10-Q · filed 2026-05-07 | ||||||
| 2024-12-31 | 7.32M shares 10-K · filed 2026-02-26 | ||||||
| 2024-09-30 | 6.97M shares 10-Q · filed 2025-11-05 | 6.97M shares 10-Q · filed 2024-11-07 | 6.97M shares 10-Q · filed 2025-11-05 | 6.97M shares 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 6.74M shares 10-Q · filed 2025-08-05 | 6.74M shares 10-Q · filed 2025-08-05 | |||||
| 2024-03-31 | 6.95M shares 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | 5.89M shares 10-K · filed 2026-02-26 | 5.89M shares 10-K · filed 2024-03-27 | |||||
| 2023-09-30 | 5.86M shares 10-Q · filed 2024-11-07 | 5.86M shares 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 6.05M shares 10-Q · filed 2024-08-08 | 6.05M shares 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | 5.85M shares 10-Q · filed 2024-05-10 | ||||||
| 2022-12-31 | 4.03M shares 10-K · filed 2024-03-27 | ||||||
| 2022-09-30 | 4.00M shares 10-Q · filed 2023-11-09 | 4.00M shares 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 3.85M shares 10-Q · filed 2023-08-10 | 3.85M shares 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | 3.55M shares 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 2.92M shares 10-K · filed 2023-03-28 | ||||||
| 2021-09-30 | 2.90M shares 10-Q · filed 2022-11-09 | 2.90M shares 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | 2.66M shares 10-Q · filed 2022-08-10 | 2.66M shares 10-Q · filed 2022-08-10 | |||||
| 2021-03-31 | 17.82M shares 10-Q · filed 2022-05-16 | ||||||
| 2020-12-31 | 17.67M shares 10-K · filed 2022-03-28 | ||||||
| 2020-09-30 | 1.37M shares 10-Q · filed 2021-11-10 | 1.37M shares 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | 1.42M shares 10-Q · filed 2021-08-16 | 1.42M shares 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | 1.39M shares 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |